• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction.

作者信息

Blajchman M A, Goldman M, Freedman J J, Sher G D

机构信息

McMaster University, Hamilton Ontario, Candada.

出版信息

Transfus Med Rev. 2001 Jan;15(1):1-20. doi: 10.1053/tmrv.2001.19946.

DOI:10.1053/tmrv.2001.19946
PMID:11149975
Abstract
摘要

相似文献

1
Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction.
Transfus Med Rev. 2001 Jan;15(1):1-20. doi: 10.1053/tmrv.2001.19946.
2
Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement.白细胞普遍减少时代预防输血后巨细胞病毒感染：一项共识声明。
Transfusion. 2001 Apr;41(4):560-9. doi: 10.1046/j.1537-2995.2001.41040560.x.
3
Polymerase chain reaction based assessment of leukoreduction efficacy using a cytomegalovirus DNA transfected human T-cell line.
J Clin Virol. 1998 Aug 20;11(2):109-16. doi: 10.1016/s1386-6532(98)00047-6.
4
Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation.输血传播巨细胞病毒及巨细胞病毒病缓解情况调查
Arch Pathol Lab Med. 2017 Dec;141(12):1705-1711. doi: 10.5858/arpa.2016-0461-OA. Epub 2017 Aug 29.
5
Prevention of transfusion-transmitted cytomegalovirus infection.输血传播巨细胞病毒感染的预防
Transfus Med. 1999 Jun;9(2):115-23. doi: 10.1046/j.1365-3148.1999.00193.x.
6
AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections.AABB委员会报告：减少输血传播的巨细胞病毒感染
Transfusion. 2016 Jun;56(6 Pt 2):1581-7. doi: 10.1111/trf.13503. Epub 2016 Mar 10.
7
Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?在普遍白细胞去除术时代，造血干细胞移植受者是否仍需要对血液制品进行巨细胞病毒检测？
Biol Blood Marrow Transplant. 2013 Dec;19(12):1719-24. doi: 10.1016/j.bbmt.2013.09.013. Epub 2013 Oct 5.
8
Transfusion-associated cytomegalovirus infections.输血相关巨细胞病毒感染
Rev Infect Dis. 1983 Nov-Dec;5(6):977-93. doi: 10.1093/clinids/5.6.977.
9
[Post-transfusional cytomegalovirus infections: incidence and methods of prevention. CMV group of SNTS].[输血后巨细胞病毒感染：发病率及预防方法。苏联输血与血液学研究所巨细胞病毒研究小组]
Rev Fr Transfus Hemobiol. 1991 May;34(3):213-32. doi: 10.1016/s1140-4639(05)80067-x.
10
[Post-transfusion cytomegalovirus infections. The position in 1987].[输血后巨细胞病毒感染。1987年的情况]
Rev Fr Transfus Immunohematol. 1987 Nov;30(4):331-6. doi: 10.1016/s0338-4535(87)80065-x.

引用本文的文献

1
What Laboratory Tests and Physiologic Triggers Should Guide the Decision to Administer a Platelet or Plasma Transfusion in Critically Ill Children and What Product Attributes Are Optimal to Guide Specific Product Selection? From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.哪些实验室检测和生理触发因素应指导危重症儿童输注血小板或血浆的决策，以及哪些产品特性最有利于指导特定产品的选择？来自输血和贫血专家倡议-控制/避免出血。
Pediatr Crit Care Med. 2022 Jan 1;23(13 Suppl 1 1S):e1-e13. doi: 10.1097/PCC.0000000000002854.
2
Infectious complications in neonatal transfusion: Narrative review and personal contribution.新生儿输血中的感染性并发症：叙述性综述及个人贡献。
Transfus Apher Sci. 2020 Oct;59(5):102951. doi: 10.1016/j.transci.2020.102951. Epub 2020 Sep 16.
3
Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents.在美国，在促红细胞生成素时代的慢性肾脏病中的红细胞输注。
J Nephrol. 2020 Apr;33(2):267-275. doi: 10.1007/s40620-019-00680-5. Epub 2019 Nov 28.
4
Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage.术中回收用于产科出血的成本效果分析。
Anesthesiology. 2018 Feb;128(2):328-337. doi: 10.1097/ALN.0000000000001981.
5
Leucoreduction of blood components: an effective way to increase blood safety?血液成分白细胞滤除：提高血液安全性的有效方法？
Blood Transfus. 2016 May;14(2):214-27. doi: 10.2450/2015.0154-15. Epub 2015 Dec 16.
6
Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis.在波兰引入病原体灭活技术：成本效益分析。
Transfus Med Hemother. 2015 May;42(3):158-65. doi: 10.1159/000371664. Epub 2015 Apr 16.
7
Effects of Prestorage Leukoreduction on the Rate of Febrile Nonhemolytic Transfusion Reactions to Red Blood Cells in a Tertiary Care Hospital.三级护理医院中储存前白细胞滤除对红细胞发热性非溶血性输血反应发生率的影响。
Ann Med Health Sci Res. 2015 May-Jun;5(3):185-8. doi: 10.4103/2141-9248.157498.
8
Transfusion medicine problems and solutions for the pediatric hematologist/oncologist.儿科血液科医生/肿瘤学家的输血医学问题及解决方案。
Pediatr Blood Cancer. 2012 Jul 1;58(7):1106-11. doi: 10.1002/pbc.24077. Epub 2012 Jan 11.
9
Prevention of transfusion-transmitted cytomegalovirus in low-birth weight infants (≤1500 g) using cytomegalovirus-seronegative and leukoreduced transfusions.采用巨细胞病毒阴性和白细胞减少输血预防低体重儿（≤1500 克）输血传播巨细胞病毒。
Transfus Med Rev. 2011 Apr;25(2):125-32. doi: 10.1016/j.tmrv.2010.11.004. Epub 2011 Feb 23.
10
Leukoreduced blood components: Advantages and strategies for its implementation in developing countries.白细胞滤除血液成分：在发展中国家实施的优势与策略
Asian J Transfus Sci. 2010 Jan;4(1):3-8. doi: 10.4103/0973-6247.59384.